Was that in the rare diseases or with thalassemia?
DR. MARKS: There were hepatic, I probably will call Dr. Ford here to make comments on this but there was a patient who had the drug-induced hepatitis that was a thalassemic patient. DR. ALLEN: Dr. Ford, would you please identify yourself for the recorder? DR. FORD: John Ford, Novartis. The transaminase elevations were scattered across all populations. They weren’t limited either to thalassemia or the rare anemic categories. DR. GHANY: If I could just follow up on that question, I was actually interested in the two patients who had ALT elevations greater than five times upper limit of normal. Did that occur in patients with higher underlying total body irons? Did they have underlying liver disease and did the total serum bilirubin rise in those two patients/ DR. MARKS: First of all the total serum bilirubin did not rise significantly. In the patient with beta-thalassemia that had drug-induced, what we would associate which could have been drug-induced hepatitis that patient had a higher